First Tracks Biotherapeutics, I
TRAX
Positions held
Your positionsTRAX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- First Tracks Biotherapeutics operates in the biotechnology sector, which is known for its potential to deliver groundbreaking therapies and innovations, attracting significant investor interest.
- The company's market cap stands at approximately $1.12 billion, indicating a substantial valuation in the biotech space.
- Analysts have a strong buy recommendation for TRAX, with a target mean price of $70.0.
- The company has not generated any revenue in recent quarters, which raises concerns about its financial viability and sustainability.
- In the most recent quarter, TRAX reported a net income loss of $33.374 million, continuing a trend of negative earnings over the past several quarters.
- The stock has a strong sell signal with a score of -19.00, indicating significant bearish sentiment among analysts.
Fundamentals
| Market cap | $1.14B | Enterprise value | $980.06M | Trailing P/E | — | Forward P/E | -8.93 |
| PEG | — | Price / book | 6.71 | Beta | — | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | — | ROA | — | Debt / equity | 0.03 |
| Current ratio | 14.28 | Free cash flow | — | Analyst recommendation | strong_buy | Mean target | $70.58 |
| 52w high | $49.91 | 52w low | $14.72 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M |
| Op margin | — | — | — | — |
| Net income | -$33.4M | -$50.5M | -$42.4M | -$47.2M |
| Gross margin | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | -$34.9M | -$52.8M | -$45.9M | -$51.3M |
Yearly (6y)
| 2024 | 2023 | |
|---|---|---|
| Revenue | $0.0M | $0.0M |
| Op margin | — | — |
| Net income | -$164M | -$106M |
| Gross margin | — | — |
| Gross profit | — | — |
| Operating income | -$181M | -$118M |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-30 · Canaccord Genuity Initiates First Tracks Biotherapeutics at Buy With $50 Price Target
2026-09-26 · AnaptysBio (ANAB) Reports a Tax-Driven Profit. When Will Royalties Fund Shareholder Returns?
2026-09-18 · Evercore ISI Initiates First Tracks Biotherapeutics With Outperform Rating, $65 PT
2026-09-16 · Guggenheim Initiates First Tracks Biotherapeutics at Buy
2026-08-26 · First Tracks Biotherapeutics Announces Participation in September Investor Conferences
2026-08-13 · Wedbush Adjusts PT on First Tracks Biotherapeutics to $70 From $60, Maintains Outperform Rating
2026-08-12 · First Tracks Biotherapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
2026-08-10 · UBS Adjusts First Tracks Biotherapeutics PT to $65 From $45, Maintains Buy Rating
2026-07-27 · Wedbush Adjusts First Tracks Biotherapeutics Price Target to $60 From $30, Maintains Outperform Rating
2026-07-27 · Top Premarket Gainers
Price (daily)
Full chart · RSI · MACD · patterns